Display options
Cite
Cacciapuoti F, Magro VM, Caturano M, et al. The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study. J Cardiovasc Echogr. 2017;27(4):126-131doi: 10.4103/jcecho.jcecho_6_17.
Cacciapuoti, F., Magro, V. M., Caturano, M., Lama, D., & Cacciapuoti, F. (2017). The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study. Journal of cardiovascular echography, 27(4), 126-131. https://doi.org/10.4103/jcecho.jcecho_6_17
Cacciapuoti, Federico, et al. "The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study." Journal of cardiovascular echography vol. 27,4 (2017): 126-131. doi: https://doi.org/10.4103/jcecho.jcecho_6_17
Cacciapuoti F, Magro VM, Caturano M, Lama D, Cacciapuoti F. The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study. J Cardiovasc Echogr. 2017 Oct-Dec;27(4):126-131. doi: 10.4103/jcecho.jcecho_6_17. PMID: 29142810; PMCID: PMC5672684.
Copy Download .nbib Format: NLM
Share it on

J Cardiovasc Echogr. 2017 Oct-Dec;27(4):126-131. doi: 10.4103/jcecho.jcecho_6_17.

The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study.

Journal of cardiovascular echography

Federico Cacciapuoti, Valerio Massimo Magro, Michele Caturano, Diana Lama, Fulvio Cacciapuoti

Affiliations

  1. Department of Internal Medicine, Ambulatory of Echocardiography, "Luigi Vanvitelli" University, Naples, Italy.

PMID: 29142810 PMCID: PMC5672684 DOI: 10.4103/jcecho.jcecho_6_17

Abstract

BACKGROUND: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm. Its action consists in reducing heart rate (HR) and improving the time of left ventricular (LV) diastolic filling. The aim of this study was to evaluate the effects of IVA added to conventional therapy on patients with diastolic heart failure (DHF) and preserved ejection fraction (HFpEF).

METHODS: We evaluated 25 patients with DHF in the New York Heart Association (NYHA) Class II-III and sinus rhythm. In these, IVA per os (5 mg/twice a day) was added to the conventional medical therapy and given for 12 weeks. Immediately before the beginning of IVA therapy and 3 months later, patients underwent echocardiographic evaluation by two-dimensional (2D) ultrasound and tissue Doppler imaging (TDI). The patterns of diastolic mitral inflow and pulmonary venous flow were recorded using 2D echocardiography, while the diastolic phase of mitral flow was recorded by TDI, from the lateral mitral annulus.

RESULTS: Three months after the addition of IVA to conventional treatment, HR significantly decreased in comparison to the baseline values. On the contrary, the echocardiographic indexes of LV diastolic dysfunction improved.

CONCLUSIONS: These results testify that the addition of IVA to conventional therapy in patients with HFpEF can improve LV diastolic function evaluated by 2D and tissue Doppler-echocardiographic patterns. These Doppler-echocardiographic results match with the clinical improvement of patients evaluated.

Keywords: Diastolic heart failure with preserved ejection fraction; Doppler-echocardiographic parameters; ivabradine; left ventricular diastolic function

Conflict of interest statement

There are no conflicts of interest.

References

  1. Br J Pharmacol. 2008 Dec;155(7):970-1 - PubMed
  2. J Am Coll Cardiol. 2003 May 7;41(9):1590-7 - PubMed
  3. J Am Coll Cardiol. 2013 Oct 8;62(15):1330-8 - PubMed
  4. J Am Coll Cardiol. 1995 Dec;26(7):1565-74 - PubMed
  5. Cardiology. 2010;117(3):234-42 - PubMed
  6. Cardiovasc Res. 1999 Aug 1;43(2):344-53 - PubMed
  7. ESC Heart Fail. 2014 Dec;1(2):94-102 - PubMed
  8. J Am Coll Cardiol. 1988 Aug;12(2):426-40 - PubMed
  9. Drugs Today (Barc). 2008 Mar;44(3):171-81 - PubMed
  10. J Am Soc Echocardiogr. 2009 Feb;22(2):107-33 - PubMed
  11. Circulation. 2000 Oct 10;102(15):1788-94 - PubMed
  12. Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H672-9 - PubMed
  13. J Am Coll Cardiol. 1993 Jul;22(1):318-25 - PubMed
  14. Eur Heart J. 2007 Oct;28(20):2539-50 - PubMed
  15. Am J Cardiol. 1998 Sep 15;82(6):756-61 - PubMed
  16. Br J Pharmacol. 1994 May;112(1):37-42 - PubMed
  17. Circulation. 2004 Aug 17;110(7):796-802 - PubMed
  18. Cardiol Clin. 2000 Aug;18(3):571-86 - PubMed
  19. J Am Coll Cardiol. 2004 Feb 4;43(3):317-27 - PubMed
  20. Drugs. 2007;67 Suppl 2:35-41 - PubMed
  21. Circulation. 2015 Nov 3;132(18):1719-25 - PubMed
  22. Am J Cardiol. 1997 Apr 1;79(7):921-8 - PubMed
  23. J Am Coll Cardiol. 1999 Sep;34(3):802-9 - PubMed
  24. Am Heart J. 1987 Jun;113(6):1489-94 - PubMed
  25. PLoS One. 2012;7(6):e39394 - PubMed
  26. Am Heart J. 1993 Apr;125(4):1148-54 - PubMed
  27. N Engl J Med. 2003 May 15;348(20):2007-18 - PubMed
  28. Int J Cardiol. 2015;187:9-11 - PubMed
  29. Int J Cardiol. 2011 Sep 1;151(2):218-24 - PubMed
  30. Circulation. 2008 May 6;117(18):2377-87 - PubMed
  31. Circulation. 1990 Aug;82(2 Suppl):I59-67 - PubMed
  32. Br J Clin Pharmacol. 2006 Feb;61(2):127-37 - PubMed
  33. J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14 - PubMed
  34. J Am Soc Echocardiogr. 2016 Apr;29(4):277-314 - PubMed
  35. Am J Physiol Heart Circ Physiol. 2003 Feb;284(2):H676-82 - PubMed
  36. Eur Heart J. 2006 Jan;27(1):65-75 - PubMed
  37. Adv Ther. 2010 Mar;27(3):160-7 - PubMed

Publication Types